MESO

Mesoblast (MESO)

About Mesoblast (MESO)

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.

Details

Daily high

$17.08

Daily low

$16.72

Price at open

$17.03

52 Week High

$21.50

52 Week Low

$12.66

Market cap

2.2B

Dividend yield

0.00%

Volume

211,810

Avg. volume

256,491

P/E ratio

-22.94

Mesoblast News